4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer
(BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. West German
Study Group and "Arbeitsgemeinschaft Gynäkologische Onkologie" (WSG-AGO) EC-Doc is a large
trial evaluating modern sequential taxane-based chemotherapy in the subgroup with 1-3
involved lymph nodes (LN).